TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23988802
Drug: Epidural corticosteroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural corticosteroid injection of 40 mg methylprednisolone acetate
Study: 23928873
Drug: Oral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral appliance therapy
Study: 15136320
Drug: High-dose antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antioxidants
Study: 11181667
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg/m(2)/d
Study: 11181667
Drug: Dexamethasone 18
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 18 mg/m(2)/d
Study: 11181667
Drug: Dexamethasone 150
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 150 mg/m(2)/d
Study: 11181667
Drug: Standard-dose corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose corticosteroids (prednisolone 40 mg/m(2)/d or dexamethasone < 6 mg/m(2)/d)
Study: 9134141
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg, maximum dose 12 mg)
Study: 3428347
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 750 mg theophylline (2 capsules Euphylong 375)
Study: 3428347
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline infusion corresponding to 506 mg theophylline over 8 h (63 mg.h‐1)
Study: 6240568
Drug: GRF1-44 (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRF1-44 (administered over 2 days in 6- and 18-h intervals)
Study: 15982350
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of influenza vaccine
Study: 23650780
Drug: BOMT1 (Bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOMT1 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 2 x 500 mg, tetracycline 2 x 500 mg; for 14 days)
Study: 23650780
Drug: BOMT2 (Bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOMT2 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 3 x 500 mg, tetracycline 4 x 500 mg; for 14 days)
Study: 11289483
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin combined with glibenclamide (n = 19)
Study: 11289483
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin combined with metformin (n = 17)
Study: 11289483
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin combined with glibenclamide and metformin (n = 17)
Study: 11289483
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of NPH insulin (n = 23)
Study: 20378197
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin therapy
Study: 3217756
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg/day
Study: 3217756
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 200 mg/day
Study: 23974642
Drug: Tafamidis 20
Normalized name: TAFAMIDIS 20MG TAB UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 20 mg once daily
Study: 21419776
Drug: Whole inactivated
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole inactivated vaccines
Study: 21419776
Drug: Subunit vaccines
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit vaccines
Study: 19195817
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of epirubicin 75 mg/m² and docetaxel 75 mg/m²
Study: 11583478
Drug: GW420867X 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW420867X 1200 mg
Study: 2607268
Drug: 1.8 ml
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Study: 2607268
Drug: 3.6 ml
Normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 ml of 2% lidocaine with 1:200,000 epinephrine
Study: 30684002
Drug: High-dose RAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose RAI therapy (3700 MBq)
Study: 30684002
Drug: Low-dose RAI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RAI therapy (1110 MBq)
Study: 28632666
Drug: Low-Intensity Pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) treatment for 2 minutes a day at 100 KHz frequency
Study: 19694184
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as ER capsules
Study: 19694184
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as plain capsules
Study: 19694184
Drug: Budesonide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (3 mg) without grapefruit juice
Study: 16973647
Drug: Ropivacaine 0.2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2%, 1 ml kg(‐1) with fentanyl 1 microg kg(‐1)
Study: 16973647
Drug: Ropivacaine 0.2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2%, 1 ml kg(‐1) with saline
Study: 11139102
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion (0.3 microg/kg/h)
Study: 11139102
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion plus intrathecal morphine
Study: 31288863
Drug: Sufentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil infusion
Study: 9417395
Drug: Hydroxyzine 50
Normalized name: hydroxyzine hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 50 mg, abrupt or progressive withdrawal
Study: 1348430
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment (dosage changed)
Study: 3254767
Drug: Oral high-frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral high-frequency oscillation (OHFO)
Study: 25530160
Drug: Intradermal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal capsaicin injection at 1 mm depth
Study: 25530160
Drug: Intradermal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal capsaicin injection at 3 mm depth
Study: 25530160
Drug: Intradermal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal capsaicin injection at 5 mm depth
Study: 25530160
Drug: Intradermal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal capsaicin injection at 7 mm depth
Study: 12850864
Drug: Metformin, 850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 850 mg twice daily throughout the cycle
Study: 8998891
Drug: Ketorolac (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (60 mg followed by 30 mg)
Study: 8998891
Drug: Meperidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (100 mg or placebo)
Study: 2007041
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg IV
Study: 2007041
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg IV and Metoclopramide 10 mg IV
Study: 29098908
Drug: Desoximetasone 0.25%
Normalized name: DESOXIMETASONE 0.25% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desoximetasone 0.25% topical spray
Study: 16673804
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% spray
Study: 18645542
Drug: J‐Tip jet
Approvals — FDA: no, EMA: no, PMDA: no
Description: J‐Tip jet injection of 1% buffered lidocaine
Study: 18645542
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% ELA‐Max
Study: 16585868
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel and cisplatin (25 mg/m cisplatin and 35 mg/m docetaxel once a week for 3 weeks followed by 1 week without treatment)
Study: 16585868
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel and cisplatin
Study: 11843382
Drug: Levonorgestrel implants
Normalized name: levonorgestrel Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel implants
Study: 25493596
Drug: Monthly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin-piperaquine
Study: 27076184
Drug: Daily trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily trimethoprim-sulfamethoxazole
Study: 7003032
Drug: Amantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (200 mg/day)
Study: 1728688
Drug: Cefazolin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1 gm before operation and 500 mg every 4 hours during operation)
Study: 6741802
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 to 50 mg)
Study: 20395917
Drug: Sub-conjunctival injection
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-conjunctival injection of dexamethasone and gentamicin combination (Group A)
Study: 17504616
Drug: Physio-psychological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physio-psychological treatment
Study: 17504616
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (DDAVP tablets)
Study: 2062626
Drug: Schwarz strain
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz strain measles vaccine (control)
Study: 15265250
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg
Study: 25469046
Drug: Xiaoyao pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaoyao pill
Study: 22302316
Drug: Intra-articular betamethasone
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-articular betamethasone injections (28 mg, up to four swollen joints/visit)
Study: 19398575
Drug: Epirubicin/platinum/fluoropyrimidine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/platinum/fluoropyrimidine combination chemotherapy (F group)
Study: 22773240
Drug: Octreotide long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide long-acting repeatable depot (OctLAR), maximum dose 40 mg, administered for 2 years (Year 1 and Year 2).
Study: 22773240
Drug: Octreotide long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide long-acting repeatable depot (OctLAR), administered for 2 years (Year 1 and Year 2).
Study: 19682194
Drug: p.o. omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. omeprazole 80 mg bolus followed by 40 mg every 12 h for 72 h
Study: 19682194
Drug: i.v. omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. omeprazole 80 mg followed by infusion 8 mg/h for 72 h
Study: 19682194
Drug: p.o. pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o. pantoprazole 80 mg bolus followed by 80 mg every 12 h for 72 h
Study: 19682194
Drug: i.v. rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. rabeprazole 80 mg followed by infusion 8 mg/h for 72 h
Study: 19682194
Drug: No proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: No proton pump inhibitor treatment
Study: 11592359
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg CII
Study: 10346406
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (50 ml of 50% glucose)
Study: 26884472
Drug: Intramuscular glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intramuscular glucagon (1 mg)
Study: 23975860
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus medication education (access to information booklets and eight 30-min face-to-face counselling sessions over 4 weeks)
Study: 11141388
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin (LVF), 500 mg v.o. every 24 h
Study: 11141388
Drug: Intravenous amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amoxicillin/clavulanate (AMX/CL), 1.02 g i.v. every 8 h
Study: 11141388
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (CTX), 1 g i.v. every 12 h
Study: 20934833
Drug: Intervention pharmacies
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention pharmacies received weekly updates on EC, fliers with three key messages on EC, and information, education, and communication materials.
Study: 16536247
Drug: Narcotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Narcotic administration (as morphine equivalents)
Study: 16536247
Drug: Initial HCAT
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial HCAT administration
Study: 12885371
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (RLX) 60 mg daily for 12 months
Study: 1679661
Drug: Intravenous celiprolol
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous celiprolol (8 mg)
Study: 9602984
Drug: Co-amoxiclav (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (500 mg three times daily for 10 days)
Study: 8011967
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone dose of 0.8 mg kg‐1
Study: 8011967
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone dose of 0.66 mg kg‐1
Study: 25346460
Drug: Propofol (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (6-8 mg/kg/h)
Study: 23272985
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment strategy (including pharmacological and non-pharmacological therapy)
Study: 21489819
Drug: Medical standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical standard therapy (physiotherapy)
Study: 16420547
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (mostly semisynthetic penicillin)
Study: 31899823
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 6 months
Study: 28650326
Drug: CofNovex plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CofNovex plus (EMA) syrup
Study: 16505650
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day, group A)
Study: 12926583
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm (T)
Study: 10856536
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluvastatin alone
Study: 10856536
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluvastatin + 400 mg bezafibrate
Study: 24783914
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice weekly) with background Methotrexate
Study: 20367669
Drug: APS 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: APS 5% lotion
Study: 15818486
Drug: Innovative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative treatment (directly from step I to step III of the WHO analgesic ladder)
Study: 15818486
Drug: Innovative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative treatment
Study: 12014724
Drug: 4 mg/day
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/day tegaserod
Study: 12014724
Drug: 12 mg/day
Normalized name: EMSAM 12 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/day tegaserod
Study: 9599499
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for six weeks
Study: 8025768
Drug: UK,74505 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK,74505 25 mg
Study: 8025768
Drug: UK,74505 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK,74505 100 mg
Study: 2663343
Drug: 7‐mono‐hydroxyethylrutoside and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐mono‐hydroxyethylrutoside and acetylsalicylic acid combination
Study: 23313654
Drug: Tdap-IPV and
Normalized name: acellular pertussis vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap-IPV and inactivated influenza vaccine administered concomitantly (Group 1)
Study: 16468062
Drug: Naloxone (NAL)
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone (NAL) 0.1 mg kg(‐1)
Study: 9373790
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial chemotherapy using implanted reservoirs (Epirubicin 40 mg/m2 every month)
Study: 9373790
Drug: Conventional transcatheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional transcatheter arterial chemotherapy (Epirubicin 60 mg/m2 every 3 months)
Study: 1492848
Drug: Flupirtine maleate
Normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine maleate 50 mg
Study: 6342637
Drug: Flupirtine maleate
Normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine maleate 100 mg
Study: 1492848
Drug: Flupirtine maleate
Normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine maleate 300 mg
Study: 23765238
Drug: Adjuvant gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant gemcitabine chemotherapy
Study: 22836057
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose radiation therapy (0.6 Gy in 6 fractions of 0.1 Gy twice weekly)
Study: 22836057
Drug: Reirradiation (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reirradiation (standard dosage) offered to patients with insufficient pain relief after 3 months
Study: 17988236
Drug: Tapering prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering prednisolone
Study: 17988236
Drug: Predocol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predocol 40 mg/day
Study: 17988236
Drug: Predocol 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predocol 60 mg/day
Study: 12028242
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (37.5 to 225 mg/day)
Study: 7138048
Drug: 0.1% anthralin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% anthralin combined with UV-B therapy
Study: 7138048
Drug: 0.01% anthralin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% anthralin combined with UV-B therapy
Study: 30302940
Drug: Pre-hospital administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital administration of ticagrelor
Study: 30302940
Drug: In-hospital administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital administration of ticagrelor
Study: 24144243
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light and melatonin capsules
Study: 19176561
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin treatment (control)
Study: 17660640
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate (40 mg/kg)
Study: 558950
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg)
Study: 17660640
Drug: Both drug
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drug regimens (chloral hydrate and diazepam)
Study: 11598383
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin (15 mU/kg x min)
Study: 11598383
Drug: Low insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low insulin (1.5 mU/kg x min)
Study: 9594683
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 supplementation with isoniazid therapy
Study: 9594683
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with isoniazid therapy
Study: 25592341
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid treatment
Study: 31068272
Drug: Bictegravir 50
Normalized name: bictegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Study: 23038220
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (Dar), cumulative dose 11.1 µg/kg b.w. over 8 months
Study: 12414848
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with daily injections of 0.4 mg GH/d (group A)